Recent trends in impurity profiling and forced degradation of antihypertensive drugs

References

• Nageswararao, R.; Nagaraju, V. An Overview of the Recent Trends in Development of HPLC Methods for Determination of Impurities in Drugs. J. Pharm. Biomed. Anal. 2003, 33, 335–377.
   PubMed Web of Science ®Google Scholar
• Saireddy, U. Review – Impurity Profiling. Eur. J. Pharm. Med. Res. 2017, 4, 238–244.
   Google Scholar
• Jain, D.; Basniwal, P. K. Forced Degradation and Impurity Profiling: Recent Trends in Analytical Perspectives. J. Pharm. Biomed. Anal. 2013, 86, 11–35.
   PubMed Web of Science ®Google Scholar
• Patil, P. P.; Kasture, V. S.; Prakash, K. V. Impurity Profiling Emerging Trends in Quality Control of Pharmaceuticals. Int. J. Pharm. Chem. 2015, 05, 01–10.
   Google Scholar
• Bartos, D.; Gorog, S. Recent Advances in the Impurity Profiling of Drugs. Curr. Pharm. Anal. 2008, 4, 215–230.
   Web of Science ®Google Scholar
• Tzanavaras, P. D. Recent Advances in the Analysis of Organic Impurities of Active Pharmaceutical Ingredients and Formulations: A Review. Curr. Org. Chem. 2010, 14, 2348–2364.
   Web of Science ®Google Scholar
• Que, F.; Norwood, D. L. Identification of Pharmaceutical Impurities. J. Liq. Chromatogr. Relat. Technol. 2007, 30, 877–935.
   Web of Science ®Google Scholar
• Pilaniya, K.; Chandrawanshi, H. K.; Pilaniya, U.; Manchandani, P.; Jain, P.; Singh, N. Recent Trends in the Impurity Profile of Pharmaceuticals. J. Adv. Pharm. Technol. Res. 2010, 1(1), 103–208.
   Google Scholar
• Bari, S. B.; Kadam, B. R.; Jaiswal, Y. S.; Shirkhedkar, A. A. Impurity Profile: Significance in Active Pharmaceutical Ingredient. Eurasian J. Anal. Chem. 2007, 2, 32–53.
   Google Scholar
• Nagpal, S.; Karan, Upadhyay, A.; Bhardwaj, T. R.; Thakkar, A. A. Review on Need and Importance of Impurity Profiling. Curr. Pharm. Anal. 2011, 7, 62–70.
   Web of Science ®Google Scholar
• Vyas, V. K.; Ghate, M.; Ukawala, R. D. Recent Advances in Characterization of Impurities – Use of Hyphenated LC–MS Technique. Curr. Pharm. Anal. 2010, 6, 199–306.
   Web of Science ®Google Scholar
• Katny, M.; Frankowski, M. Impurities in Drug Products and Active Pharmaceutical Ingredients. Crit. Rev. Anal. Chem. 2016, 47, 187–193.
   PubMed Web of Science ®Google Scholar
• The United State Pharmacopoeia USP 24. The National Formulary NF 19. 2000. Twinbrook Parkway, Rockville, MD: United State Pharmacopeial Convention, Inc. 12601, 1998; 1876–1878 pp., 20852.
   Google Scholar
• ICH. Impurities in New Drug Substances Q3A (R2), International Conference on Harmonization, 2006; IFPMA: Geneva, 2 June 2006.
   Google Scholar
• Balram, V. Recent Advances in the Determination of Elemental Impurities in Pharmaceuticals-Status. Challenges and Moving Frontiers. Trends Anal. Chem. 2016, 80, 83–95.
   Web of Science ®Google Scholar
• Muller, A. L. H.; Oliveria, J. S. S.; Mello, P. A.; Muller, E. I.; Flores, E. M. M. Study and Determination of Elemental Impurities by ICP-MS in Active Pharmaceutical Ingredients Using Single Reaction Chamber Digestion in Compliance with USP Requirements. Talanta 2015, 136, 161–169.
   PubMed Web of Science ®Google Scholar
• Wollein, U.; Bauer, B.; Hebernegg, R.; Scramek, N. Potential Metal Impurities in Active Pharmaceutical Substances and Finished Medicinal Products – A Market Surveillance Study. Eur. J. Pharm. Sci. 2015, 77, 100–105.
   PubMed Web of Science ®Google Scholar
• ICH. Guideline for Elemental Impurities Q3D, International Conference on Harmonization, 2014; IFPMA: Geneva, 16 December 2014.
   Google Scholar
• Bari, S. B.; Jain, S. B.; Shirkhedkar, A.; Sonawane, A.; Mhaske, A. J.; Gawad, J. B. Impurities in Pharmaceuticals: A Review. World J. Pharm. Res. 2015, 4(10), 2932–2947.
   Google Scholar
• ICH. Impurities in New Drug Products Q3B (R2), International Conference on Harmonization, 2016; IFPMA: Geneva, 2 June 2016.
   Google Scholar
• ICH. Impurities: Guideline for Residual Solvents Q3C (R6), International Conference on Harmonization, 2016; IFPMA: Geneva, 9 November 2016.
   Google Scholar
• Guidance for Industry, Q3A Impurities in New Drug Substances. U.S. Department of Health and Human Services Food and Drug Administration: U.S., 2008.
   Google Scholar
• Snodin, D. J.; McCrossen, S. D. Guidelines and Pharmacopoeial Standards for Pharmaceutical Impurities: Overview and Critical Assessment. Regul. Toxicol. Pharmacol. 2012, 63, 298–312.
   PubMed Web of Science ®Google Scholar
• Venkatesan, P.; Valliappan, K. Impurity Profiling: Theory and Practice. J. Pharm. Sci. Res. 2014, 6, 254–259.
   Google Scholar
• Blessy, M.; Patel, R. D.; Prajapati, P. N.; Agrawal, Y. K. Development of Forced Degradation and Stability Indicating Studies of Drugs – A Review. J. Pharm. Anal. 2013, 4, 159–165. doi:10.1016/j.jpha.2013.09.003.
   PubMedGoogle Scholar
• Aslante, K. M.; Ando, A.; Brown, R.; Encing, J.; Hatajik, T. D.; Kong, W.; Tsuda, Y. The Role of Degradants Profiling in Active Pharmaceutical Ingredients and Drug Products. Adv. Drug Deliv. Rev. 2007, 59, 29–37.
   PubMed Web of Science ®Google Scholar
• Brummer, H. How to Approach a Forced Degradation Study. Life Sci. Technol. Bull. 2011, 31, 1–4.
   Google Scholar
• Ramchandra, B. Development of Impurity Profiling Methods Using Modern Analytical Techniques. Crit. Rev. Anal. Chem. 2016, 47, 24–36. doi:10.1080/10408347.2016.1169913.
   PubMed Web of Science ®Google Scholar
• ICH. Stability Testing of New Drug Substances and Products Q1A (R2), International Conference on Harmonization, 2003; IFPMA: Geneva, 6 February 2003.
   Google Scholar
• ICH. Stability Testing: Photostability Testing of New Drug Substances and Products Q1B, International Conference on Harmonization, 1996; IFPMA: Geneva, 6 November 1996.
   Google Scholar
• ICH. Stability Testing for New Dosage Forms Q1C, International Conference on Harmonization, 1996; IFPMA: Geneva, 6 November 1996.
   Google Scholar
• ICH. Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products Q1D, International Conference on Harmonization, 2002; IFPMA: Geneva, 1 February 2002.
   Google Scholar
• ICH. Evaluation for Stability Data Q1E, International Conference on Harmonization, 2003; IFPMA: Geneva, August 2003.
   Google Scholar
• World Health Organization. Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products; World Health Organisation: Geneva, 2009; Vol. 953, 87–130 pp.
   Google Scholar
• Shah, S. R.; Patel, M. A.; Naik, M. V.; Pradhan, P. K.; Upadhyay, U. M. Recent Approaches of Impurity Profiling in Pharmaceutical Analysis: A Review. Int. J. Pharm. Sci. Res. 2012, 3, 3603–3617.
   Google Scholar
• Naguib, I. A.; Abdelaleem, A.; Draz, M. E.; Zaazaa, H. E. Development and Validation of RP-HPLC Method for Determination of Hydrochlorothiazide, Amiloride Hydrochloride and Related Impurities in a Bulk and Pharmaceutical Dosage Forms. J. Anal. Chem. Lett. 2015, 5(2), 85–93.
   Google Scholar
• Srinivasu, P.; Subbarao, D. V.; Vegesna, R. V. K.; Babu, K. S. A Validated Stability-Indicating LC Method for Acetazolamide in the Presence of Degradation Products and Its Process Related Impurities. J. Pharm. Biomed. Anal. 2010, 52, 142–148.
   PubMed Web of Science ®Google Scholar
• Franolic, J. D.; Lehr, G. J.; Barry, T. L.; Petzinger, G. Isolation of a 2:1 Hydrochlorothiazide–Formaldehyde Adduct Impurity in Hydrochlorothiazide Drug Substance by Preparative Chromatography and Characterization by Electrospray Ionization LC–MS. J. Pharm. Biomed. Anal. 2001, 26, 651–663.
   PubMed Web of Science ®Google Scholar
• Fang, X.; Bibart, R. T.; Mayr, S.; Yin, W.; Harmon, P. A.; Mccafferty, J. F.; Tyrell, R. J.; R. A. Reed. Purification and Identification of an Impurity in Bulk Hydrochlorothiazide. J. Pharm. Sci. 2001, 90, 1800–1809.
   PubMed Web of Science ®Google Scholar
• Ivanovic, D.; Alenovic, A.; Jancic, B.; Medenica, M.; Maskovic, M. Monitoring of Impurity Level of Valsartan and Hydrochlorothiazide Employing an RP-HPLC Gradient Mode. J. Liq. Chromatogr. Relat. Technol. 2007, 30, 2879–2890.
   Web of Science ®Google Scholar
• Reddy, R. S.; Krishna, R. M.; Vekaria, N. A.; Rao, S. V.; Mantena, B. P. V. Method Development and Validation for the Determination of Potential Impurities Present in Olmsartan Medoxomil and Hydrochlorothiazide in Fixed Dose Combination Drug Product by Using Reverse Phase-Ultra-Performance Liquid Chromatography Coupled with Diode-Array Detector. J. Liq. Chromatogr. Relat. Technol. 2015, 38, 1343–1354.
   Web of Science ®Google Scholar
• Ganipisetty, V. N. R.; Jalandar, D.; Gnanadev, G.; Manoj, P.; Venkata Nadh, R. A Novel Reversed Phase Liquid Chromatographic Method for the Simultaneous Determination of Potential Impurities of Bisoprololfumarate and Hydrochlorothiazide in a Fixed Dosage Form. J. Sep. Sci. Technol. 2016, 51, 1362–1369. doi:10.1080/01496395.2016.1154873.
   Web of Science ®Google Scholar
• Pandit, N. K.; Hinderliter, J. S. Degradation of Chlorthalidone in Methanol: Kinetics and Stabilization. J. Pharm. Sci. 1985, 74(8), 857–861.
   PubMed Web of Science ®Google Scholar
• Quaglia, M. G.; Farino, A. M.; Fanali, S. Determination of Chlorthalidone and Its Impurity in Bulk and Its Dosage Forms by High-Performance Thin-Layer Chromatographic Densitometry. J. Chromatogr. 1988, 456, 435–439.
   PubMed Web of Science ®Google Scholar
• Padval, M. V.; Bhargava, H. N. Liquid Chromatographic Determination of Indapamide in the Presence of Its Degradation Products J. Pharm. Biomed. Anal. 1993, 11, 1033–1036.
   Google Scholar
• Frontini, R.; Mielck, J. B. Determination and Quantitation of Bendroflumethiazide and Its Degradation Product Using HPLC. J. Liq. Chromatogr. 1992, 15(14), 2519–2528.
   Web of Science ®Google Scholar
• Miller, J. H. M.; Robrt, J. L.; Sorensen, A. M. Reversed-Phase Ion-Pair Liquid Chromatographic Method for Determining the Impurities of Furosemide. J. Pharm. Biomed. Anal. 1993, 11(3), 257–261.
   PubMed Web of Science ®Google Scholar
• Bhardwaj, S. P.; Singh, S. Study of Forced Degradation Behaviour of Enalapril Maleate by LC and LC–MS and Development of a Validated Stability-Indicating Assay Method. J. Pharm. Biomed. Anal. 2008, 46, 113–120.
   PubMed Web of Science ®Google Scholar
• Toporisic, R.; Mlakar, A.; Hvala, J.; Prislan, I.; Zupancic-Kralj, L. Identification of New Impurities of Enalaprilmaleate on Oxidation in the Presence of Magnesium Monoperoxyphthalate. J. Pharm. Biomed. Anal. 2010, 52, 294–299.
   PubMed Web of Science ®Google Scholar
• Shinde, V.; Trivedi, A.; Upadhayay, P. R.; Gupta, N. L.; Kanse, D. G.; Chikate, R. Identification of New Impurity in Lisinopril. J. Pharm. Biomed. Anal. 2007, 43, 381–386.
   PubMed Web of Science ®Google Scholar
• Zhu, P.; Wang, D.; Sun, C.; Shen, Z. Characterization of Impurities in the Bulk Drug Lisinopril by Liquid Chromatography/Ion Trap Spectrometry. J. Zhejiang Univ. Sci. B 2008, 9(5), 385–390.
   PubMed Web of Science ®Google Scholar
• Medenica, M.; Ivanovic, D.; Maskovic, M.; Jancic, B.; Malenovic, A. Evaluation of Impurities Level of Perindopril tert-Butylamine in Tablets. J. Pharm. Biomed. Anal. 2007, 44, 1087–1094.
   PubMed Web of Science ®Google Scholar
• Malenovic, A.; Dotsikas, Y.; Maskovic, M.; Jansic-Stojanovic, B.; Evanovic, D.; Medinica, M. Desirability-Based Optimization and Its Sensitivity Analysis for the Perindopril and Its Impurities Analysis in Microemulsion LC System. Microchem. J. 2011, 99, 454–460.
   Web of Science ®Google Scholar
• Narayanam, M.; Singh, S. Characterization of Stress Degradation Products of Fosinopril by Using LC-MS/TOF, MSn and On-Line H/D Exchange. J. Pharm. Biomed. Anal. 2014, 92, 135–143.
   PubMed Web of Science ®Google Scholar
• Gana, M.; Panderi, I.; Parissi-Poulou, M.; Tsantili-Kakoulidou, A. Kinetic of the Acidic and Enzymatic Hydrolysis of Benazepril HCL Studied by LC. J. Pharm. Biomed. Anal. 2002, 27, 107–116.
   PubMed Web of Science ®Google Scholar
• Shinde, V. R.; Trivedi, A.; Upadhayay, P. R.; Gupta, N. L.; Kanase, D. G.; Chikate, R. C. Isolation and Characterization of Benazepril Unknown Impurity by Chromatographic and Spectroscopic Methods. J. Pharm. Biomed. Anal. 2006, 42, 395–399.
   PubMed Web of Science ®Google Scholar
• Sahu, K.; Karthikeyan, C.; Moorthy, N. S. H. N.; Trivedi, P. A Validated UPLC Method Used for the Determination of Trandolapril and Its Degradation Products as Per ICH Guidelines. Curr. Pharm. Anal. 2011, 7(3), 182–188.
   Web of Science ®Google Scholar
• Dendeni, M.; Cimetiere, N.; Amrane, A.; Hamida, N. B. Impurity Profiling of Trandolapril Under Stress Testing: Structure Elucidation Byproducts and Development of Degradation Pathway. Int. J. Pharm. 2012, 438, 61–70.
   PubMed Web of Science ®Google Scholar
• Roskar, R.; Simoncic, Z.; Gartner, A.; Kemtec, V. Stability of New Potential ACE Inhibitor in the Aqueous Solutions of Different pH. J. Pharm. Biomed. Anal. 2009, 49, 295–303.
   PubMed Web of Science ®Google Scholar
• McCarthy, K. E.; Wang, Q.; Tsai, E. W.; Gilbert, R. E.; Ip, D. P.; Brooks, M. A. Determination of Losartan and Its Degradates in COZAAR Tablets by Reversed Phase High Performance Thin Layer Chromatography. J. Pharm. Biomed. Anal. 1998, 17, 671–677.
   PubMed Web of Science ®Google Scholar
• Zhao, Z.; Wang, Q.; Tsai, E. W.; Qin, X.; Ip, D. Identification of Losartan Degradates in Stress Tablets by LC–MS and LC–MS/MS. J. Pharm. Biomed. Anal. 1999, 20, 129–136.
   PubMed Web of Science ®Google Scholar
• Hertzog, D. L.; McCafferty, J. F.; Fang, X.; Tyrrell, R. J.; Reed, R. A. Development and Validation of Stability – Indicating HPLC Method for Simultaneous Determination of Losartan Potassium, Hydrochlorothiazide, and Their Degradation Products. J. Pharm. Biomed. Anal. 2002, 30, 747–760.
   PubMed Web of Science ®Google Scholar
• Lusina, M.; Cindric, T.; Tomaic, J.; Peko, M.; Pozaic, L.; Musulin, N. Stability Study of Losartan/Hydrochlorthiazide Tablets. J. Pharm. 2005, 291, 127–137.
   Google Scholar
• Seburg, R. A.; Ballard, J. M.; Hwang, T.; Sullivan, C. M. Photosensitize Degradation of Losartan Potassium in and Extemporaneous Suspension Formulation. J. Pharm. Biomed. Anal. 2006, 42, 411–422.
   PubMed Web of Science ®Google Scholar
• Pandey, A. K.; Rapolu, R.; Raju, C. K.; Sasalamari, G.; Goud, S. K.; Awasthi, A.; Navalgund, S. G.; Surendranath, K. V. The Novel Acid Degradation Products of Losartan: Isolation and Characterization Using Q-TOF, 2D-NMR and FTIR. J. Pharm. Biomed. Anal. 2016, 120, 65–71.
   PubMed Web of Science ®Google Scholar
• Mehta, S.; Shah, R. P.; Priyadarshi, R.; Singh, S. LC and LC–MS/TOF Studies on Stress Degradation Behavior of Candesartan Cilexetil. J. Pharm. Biomed. Anal. 2010, 52, 345–354.
   PubMed Web of Science ®Google Scholar
• Raman, B.; Sharma, B. A.; Mahale, G.; Singh, D.; Kumar, A. Investigation and Structural Elucidation of Process Related Impurity in Candesartan Cilexetil by LC/ESI-ITMS and NMR, J. Pharm. Biomed. Anal. 2011, 56, 256–263.
   Google Scholar
• Kumar, N. D. A.; Babu, K. S.; Gosada, U.; Sharma, N. A Validated Ultra High-Pressure Liquid Chromatography Method for Separation Candesartan Cilexetil Impurities and Its Degradents in Drug Product. Pharm. Methods 2012, 3(1), 31–39.
   PubMedGoogle Scholar
• Golubovic, J. B.; Protic, A. D.; Zecevic, M. L.; Otasvic, B. M. Quantitative Structure Retention Relationship Modeling in Liquid Chromatography Method for Separation of Candesartan Cilexetil and Its Degradation Products. Chemom. Intell. Lab. Syst. 2014, 140, 92–101. doi.10.1016/j.chemolab.2014.11.005
   Web of Science ®Google Scholar
• Bodapati, K.; Vaidya, J. R.; Siddhiraju, S.; Gowrisankar, D. Stability Indicating RP-HPLC Studies for the Estimation of Irbesartan and Amlodipinbesylate in Pharmaceutical Formulations and Identification and Characterization of Degradants Using LC–MS. J. Liq. Chromatogr. Technol. 2015, 38, 259–270.
   Web of Science ®Google Scholar
• Nie, J.; Xiang, B.; Fang, Y.; Wang, D. Isolation and Identification of Process Impurities in Crude Valsartan by HPLC, Mass Spectrometry, and Nuclear Magnetic Resonance Spectroscopy. J. Liq. Chromatogr. Relat. Technol. 2006, 29, 553–568.
   Web of Science ®Google Scholar
• Sampath, A.; Reddy, A. R.; Yakambaram, B.; Thirupathi, A.; Prabhakar, M. Reddy, P. P.; Reddy, V. P. Identification and Characterization of Potential Impurities of Valsartan, AT1 Receptor Antagonist. J. Pharm. Biomed. Anal. 2009, 50, 405–412.
   PubMed Web of Science ®Google Scholar
• Krishnaiah, C.; Reddy, A. R.; Kumar, R.; Mukkanti, K. Stability-Indicating UPLC Method for Determination of Valsartan and Their Degradation Product in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Forms. J. Pharm. Biomed. Anal. 2010, 53, 483–489.
   PubMed Web of Science ®Google Scholar
• Bianchini, R. M.; Castellano, P. M.; Kaufman, T. S. Characterization of Two New Potential Impurities of Valsartan Obtain Under Photo Degradation Stress Condition. J. Pharm. Biomed. Anal. 2011, 56, 16–22.
   PubMed Web of Science ®Google Scholar
• Bianchini, R. M.; Castellano, P. M.; Kaufman, T. S. Stress Testing of Valsartan. Development and Validation of a High Performance Liquid Chromatography Stability-Indicating Assay. J. Liq. Chromatogr. Relat. Technol. 2012, 35(8), 1053–1069.
   Web of Science ®Google Scholar
• Srinivasan, V.; Shivaramakrishna, H.; Karthikeyan, B. Detection, Isolation and Characterization of Principal Synthetic Route Indicative Impurity in Telmisartan. Arab. J. Chem. 2016, 9, S1516–S1522.
   Web of Science ®Google Scholar
• Mantena, B. P. V.; Rao, S. V.; AppaRao, K. M. C.; Ramakrishna, K.; Reddy, R. S. Method Development and Validation for the Determination of Potential Impurities Present in Azilsartan Medoxomil Tablets by Reverse Phase-Ultra Performance Liquid Chromatography. Anal. Chem. Lett. 2014, 4(5–6), 287–301.
   Google Scholar
• Kaushik, D.; Kaur, J.; Kaur, V. P.; Saini, B.; Bansal, Y. Forced degradation, LC-UV, MSn and LC-MS-TOF Studies on Azilsartan: Identification of a Known and Three New Degradation Impurities. J. Pharm. Biomed. Anal. 2016, 120, 202–2011.
   PubMed Web of Science ®Google Scholar
• Sun, C.; Wu, J.; Wang, D.; Pan, Y. Characterization of Novel Impurity in Bulk Drug Eprosartan by ESI/MSn and NMR. J. Pharm. Biomed. Anal. 2010, 51, 778–783.
   PubMed Web of Science ®Google Scholar
• Satheesh, B.; Pulluru, S. K.; Nitin, K.; Saravanan, D. Simultaneous Determination of Eprosartan, Hydrochlorothiazide, and Their Related Compounds in Pharmaceutical Dosage Forms by UPLC. J. Liq. Chromatogr. Relat. Technol. 2011, 34(17), 1885–1900.
   Web of Science ®Google Scholar
• Cheekatla, S.; Rupakula, R.; Reddy, B. N.; Sharada, M. Determination and Characterization of Process Impurities for Eprosartan Mesylate. J. Pharm. Res. 2013, 6, 504–509.
   Google Scholar
• Murakami, T.; Konno, H.; Fukutsu, N.; Onodera, M.; Kawasaki, T.; Kusu, F. Identification of a Degradation Product in Stressed Tablets of Olmesartan Medoxomil by the Complementary Use of HPLC Hyphenated Techniques. J. Pharm. Biomed. Anal. 2008, 47, 553–559.
   PubMed Web of Science ®Google Scholar
• Raj, S.; Kumari, K. S.; Rao, A. N.; Reddy, I. U.; Raju, M. N. Development of Stability-Indicating UPLC Method for Determination of Olmesartan Medoxomil and Its Degradation Product in Active Pharmaceutical Ingredient and Dosage Forms. J. Liq. Chromatogr. Relat. Technol. 2012, 35(8), 1011–1026.
   Web of Science ®Google Scholar
• Gricar, M.; Andrensek, S. Determination of Azide Impurity in Sartans Using Reversed-Phase HPLC with UV Detection. J. Pharm. Biomed. Anal. 2016, 125, 27–32.
   PubMed Web of Science ®Google Scholar
• Dousa, M.; Brichac, J.; Svoboda, J.; Klvana, R. Rapid HILIC Method with Fluorescence Detection Using Derivatization Reaction Utilizing O-Phthaldialdehyde for Determination of Degradation Product of Aliskiren. J. Pharm. Biomed. Anal. 2012, 66, 359–364.
   PubMed Web of Science ®Google Scholar
• Chatpalliwar, V. A.; Porwal, P. K.; Upmanayu, N. Validated Gradient Stability Indicating HPLC Method for Determining Diltiazem Hydrochloride and Related Substances in Bulk Drug and Novel Tablet Formulation. J. Pharm. Anal. 2012, 2(3), 226–237.
   PubMedGoogle Scholar
• Qin, X.; DeMarco, J.; Ip, D. P. Simultaneous Determination of Enalapril, Felodipine and Their Degradation Product in the Dosage Formulation by Reversed-Phase High-Performance Liquid Chromatography Using a Spherisorb C18 Column. J. Chromatogr. A 1995, 707, 245–254.
   Web of Science ®Google Scholar
• Cardoza, R. M.; Amin, P. D. A Stability Indicating LC Method for Felodipine. J. Pharm. Biomed. Anal. 2002, 27, 711–718.
   PubMed Web of Science ®Google Scholar
• Sudhakar, P.; Nirmala, M.; Babu, J. M.; Vyas, K.; Reddy, G. M.; Bhaskar, B. V.; Reddy, P. P.; Mukkanti, K. Identification and Characterization of Potential Impurities of Amlodipine Maleate. J. Pharm. Biomed. Anal. 2006, 40, 605–613.
   PubMed Web of Science ®Google Scholar
• Rapolu, R.; Raju, C. K.; Srinivas, K.; Awasthi, A.; Navalgund, S. G.; Surendranath, K. V. Isolation and Characterization of Novel Acid Degradation Impurity of Amlodipine Besylate Using Q-TOF, NMR, IR, and Single Crystal X-Ray. J. Pharm. Biomed. Anal. 2014, 99, 59–66.
   PubMed Web of Science ®Google Scholar
• Tiwari, R. N.; Shah, N.; Bhalani, V.; Mahajan, A. LC, MSn and LC–MS/MS Study for the Characterization of Degradation Products of Amlodipine. J. Pharm. Anal. 2014, 5(1), 33–42.
   PubMedGoogle Scholar
• Vojta, J.; Jedlicka, A.; Coufal, P.; Janeckova, L. A New, Rapid, Stability-Indicating UPLC Method for Separation and Determination of Impurities in Amlodipine Besylate, Valsartan and Hydrochlorothiazide in Their Combined Tablet Dosage Form. J. Pharm. Biomed. Anal. 2015, 109, 36–44.
   PubMed Web of Science ®Google Scholar
• Mantena, B. P. V.; Rao, S. V.; Suryakala, D.; Ramakrishna, K.; Reddy, R. S. Rapid Analytical Technique for Quantification of Specified and Unspecified Impurities Present in Amlodipine Besylate and Olmesartan Medoxomil Fixed Dose Combination Drug Product Using Ethylene-Bridged RP-UPLC Column. J. Anal. Chem. Lett. 2016, 6(6), 795–819.
   Google Scholar
• Marinkovic, V.; Agbaba, D.; Vladimirov, S.; Stankovoc, S. Simultenous HPLC Determination of Nitrendipine and Impurities of the Process of Synthesis. J. Pharm. Biomed. Anal. 2001, 24, 993–998.
   PubMed Web of Science ®Google Scholar
• Bartlett, M. G.; Spell, J. C.; Mathis, P. S.; Elagany, M. F. A.; ElZeany, B. E.; Elkawy, M. A.; Stewart, J. T. Determination of Degradation Products from the Calcium-Channel Blocker Isradipine. J. Pharm. Biomed. Anal. 1998, 18, 335–345.
   PubMed Web of Science ®Google Scholar
• Al-Ghannam, S. M.; Al-Olayan, A. M. Stability Indicating HPLC Method for the Determination of Nicardipine in Capsules and Spiked Human Plasma. Identification of Degradation Products Using HPLC/MS. Arab. J. Chem. 2014. doi: 10.1016/j.arabjc.2014.11.044
   Web of Science ®Google Scholar
• Barmpalexis, P.; Kanaze, F. I.; Georgarakis, E. Developing and Optimizing a Validated Isocratic Reversed-Phase High-Performance Liquid Chromatography Separation of Nimodipine and Impurities in Tablet Using Experimental Design Methodology. J. Pharm. Biomed. Anal. 2009, 49, 1192–1202.
   PubMed Web of Science ®Google Scholar
• Riekes, M. K.; Rauber, G. S.; Kuminek, G.; Tagliari, M. P.; Cardoso, S. G.; Stulzer, H. K. Determination of Nimodipine in the Presence of Its Degradation Product and Overall Kinetics Through a Stability-Indicating LC Method. J. Chromatogr. Sci. 2013, 51, 511–516.
   PubMed Web of Science ®Google Scholar
• Marinkovic, V. D.; Agbaba, D.; Karljikovic-Rajic, K.; Vladimirov, S.; Nedeljovic, J. M. Photochemical Degradation of Solid-State Nisoldipine Monitored by HPLC. J. Pharm. Biomed. Anal. 2003, 32, 929–935.
   PubMed Web of Science ®Google Scholar
• Ioele, G.; Oliverio, F.; Andreu, I.; Luca, M. D.; Miranda, M. A.; Ragno, G. Different Photo Degradation Behavior of Barnidipine Under Natural and Forced Irradiation. J. Photochem. Photobiol A: Chem. 2010, 215, 205–213.
   Web of Science ®Google Scholar
• Zeng, H.; Wang, F.; Zhu, B.; Zhong, W.; Shan, W.; Wang, J. Study of the Structures of Photo Degradation Impurities and Pathways of Photo Degradation of Cilnidipine by Liquid Chromatography/Q-Orbitrap Mass Spectrometry. Rapid Commun. Mass Spectrom. 2016, 30(15), 1771–1778.
   PubMed Web of Science ®Google Scholar
• Ueyama, E.; Takahashi, F.; Ohashi, J.; Konse, T.; Kishi, N.; Kano, K. Mechanistic Study on Degradation of Azelnidipine Solution Under Radical Initiator-Based Oxidative Conditions. J. Pharm. Biomed. Anal. 2012, 61, 277–283.
   PubMed Web of Science ®Google Scholar
• Atici, E. B.; Karliga, B. Identification, Synthesis and Characterization of Process Related Impurities of Benidipine HCl, Stress Testing/ Stability Studies and HPLC/UPLC Method Validations. J. Pharm. Anal. 2015, 5, 256–268. doi:10.1016/j.jpha.2015.02.001.
   PubMedGoogle Scholar
• Xu, Q.; Tan, S.; Petrova, K. Development and Validation of a Hydrophilic Interaction Chromatography Method Coupled with a Charged Aerosol Detector for Quantitative Analysis of Nonchromophoric α-Hydroxyamines. Organic Impurities of Metoprolol. J. Pharm. Biomed. Anal. 2016, 118, 242–250.
   PubMed Web of Science ®Google Scholar
• Pawlak, Z.; Clark, B. J. The Assay and Resolution of the Beta-Blocker Atenolol from Its Related Impurities in a Tablet Pharmaceutical Dosage Form. J. Pharm. Biomed. Anal. 1992, 10, 329–334.
   PubMed Web of Science ®Google Scholar
• Ceresole, R.; Moyano, M. A.; Pizzorno, M. T.; Segall, A. I. Validated Reversed-Phase HPLC Method for Determination of Atenolol in the Presence of Its Major Degradant Product. J. Liq. Chromatogr. Relat. Technol. 2006, 29(20), 3009–3019.
   Web of Science ®Google Scholar
• Tumpa, A. R.; Rakic, T. M.; Jovanovic, M. M.; Jancic-Stojanovic, B. S. Optimization of Chromatographic Separation of Acetylsalicylic Acid, Amlodipine, Impurity A of Amlodipine and Atenolol in Hydrophilic Interaction Liquid Chromatography Employing DOE Methodology. J. Liq. Chromatogr. Relat. Technol. 2015, 38, 1555–1560. doi:10.1080/10826076.2015.1077863.
   Web of Science ®Google Scholar
• Difeo, T. J.; Shuster, J. E. Determination of a Process Intermediate of Celiprolol and Its Potential Impurities by Gradient High-Performance Liquid Chromatography – Application of High Low Chromatography. J. Pharm. Biomed. Anal. 1991, 9, 823–828.
   PubMed Web of Science ®Google Scholar
• El-Gindy, A.; Ashour, A.; Abdel-Fattah, L.; Shabana, M. M. First Derivative Spectrophotometric, TLC-Densitometric, and HPLC Determination of Acebutolol HCL in Presence of Its Acid-Induced Degradation Product. J. Pharm. Biomed. Anal. 2001, 24, 527–534.
   PubMed Web of Science ®Google Scholar
• Galanopoulou, O.; Rozou, S.; Antoniadou-Vyza, E. HPLC Analysis, Isolation and Identification of a New Degradation Product in Carvedilol tablets. J. Pharm. Biomed. Anal. 2008, 48, 70–77.
   PubMed Web of Science ®Google Scholar
• Milovanovic, S.; Otasevic, B.; Zecevic, M.; Zivanovic, L.; Protic, A. Development and Validation of Reversed Phase High Performance Liquid Chromatographic Method for Determination of Moxonidine in the Presence of Its Impurities. J. Pharm. Biomed. Anal. 2012, 59, 151–156.
   PubMed Web of Science ®Google Scholar
• Ahmed, A. B.; Abdelwahab, N. S.; Abdelrahman, M. M.; Salma, F. M. Simultaneous Determination of Dimenhydrinate, Cinnarizine, and Cinnarizine Impurity by TLC and HPLC Chromatographic Methods. Bull. Faculty Pharm. Cairo Univ. 2017, 55, 163–169. doi:10.1016/j.bfopcu.2017.01.003.
   Google Scholar
• Singh, S.; Handa, T.; Narayanam, M.; Sahu, A.; Junwal, M.; Shah, R. P. A Critical Review on the Use of Modern Sophisticated Hyphenated Tools in the Characterization of Impurities and Degradation Products. J. Pharm. Biomed. Anal. 2012, 69, 148–173.
   PubMed Web of Science ®Google Scholar
• Narayanam, M.; Handa, T.; Sharma, P.; Jhajra, S.; Muthe, P. K.; Dappili, P. K.; Shah, R. P.; Singh, S. Critical Practical Aspect in the Application of Liquid Chromatography–Mass Spectrometric Study for the Characterization of Impurities and Degradation Products. J. Pharm. Biomed. Anal. 2013, 87, 191–217. doi:10.1016.j.jpba.2013.04.027.
   PubMed Web of Science ®Google Scholar
• Holm, R.; Elder, D. P. Analytical Advances in Pharmaceutical Impurity Profiling. Eur. J. Pharm. Sci. 2016, 87, 118–135.
   PubMed Web of Science ®Google Scholar
• Galea, C.; Mangelings, D.; Heyden, Y. V. Method Development for Impurity Profiling in SFC: The Selection of a Dissimilar Set of Stationary Phases. J. Pharm. Biomed. Anal. 2015, 111, 333–343.
   PubMed Web of Science ®Google Scholar
• Maggio, R. M.; Calvo, N. L.; Vignaduzzo, S. E.; Kaufman, T. S. Pharmaceutical Impurities and Degradation Products: Uses and Applications of NMR Techniques. J. Pharm. Biomed. Anal. 2014, 101, 102–122. doi:10.1016/j.jpba.2014.04.016.
   PubMed Web of Science ®Google Scholar
• Orlandini, S.; Gotti, R.; Giannini, I.; Pasquini, B.; Furlanetto, S. Development of a Capillary Electrophoresis Method for the Assay of Ramipril and Its Impurities: An Issue of Cis–Trans Isomerization. J. Chromatogr. A 2011, 1218, 2611–2617.
   PubMed Web of Science ®Google Scholar
• Torres, A. R.; Junior, S. G.; Fragoso, W. D. Multivariate Control Chart for Monitoring Captopril Stability. Microchem. J. 2015, 118, 259–265. doi:10.1016/j.microc.2014.07.017.
   Web of Science ®Google Scholar
• Pasquini, B.; Orlandini, S.; Caprini, C.; Bubba, M. D.; Innocenti, M.; Brusotti, G.; Furlanetto, S. Cyclodextrin and Solvent-Modified Micellar Electrokinetic Chromatography for the Determination of Captopril, Hydrochlorothiazide and Their Impurities: A Quality by Design Approach. Talanta 2016, 160, 332–339. doi:10.1016/j.talanta.2016.07.038.
   PubMed Web of Science ®Google Scholar
• Shen, S.; Yang, X.; Shi, Y. Application of Quantitative NMR for Purity Determination of Standard ACE Inhibitors. J. Pharm. Biomed. Anal. 2015, 114, 190–199. doi:10.1016./j.jpba.2015.05.021.
   PubMed Web of Science ®Google Scholar
• Nisal, S. R.; Kachave, R. N.; Chaudhari, S. R. Recent Trends for the Impurity Profiling of Pharmaceuticals drugs A Review. Indo Am. J. Pharm. Res. 2014, 4, 3023–3030.
   Google Scholar